화학공학소재연구정보센터
Journal of Industrial and Engineering Chemistry, Vol.20, No.4, 2490-2496, July, 2014
The development of nano-polyplex efficacious against osteoarthropathy
E-mail:
This study is a manufacturing design to reduce side effects and to increase use rate of organism by inclusion of Alendronate, a kind of bisphosphonate used for treatment and prevention of osteoporosis, into the center of W1/O/W2 multi-emulsions. We have used enteric coating materials insolvent in acid by adding adhesion property of mucous membrane. We have secured enteric nature with Eudragit by using PEO (polyethylene oxide) polymer as adhesion property of mucous membrane and have encapsulated using PVA (polyvinyl alcohol). We have conducted optimum test per phases and it was found out that the best result was achieved when we have used an ideal quantity ratio of Alendronate and PEO in 1:0.1. The quantity of PEO molecule was 300,000 and oily phase was manufactured with the addition of water phase, and L100 Type Eudragit was used for the manufacturing. We have manufactured the optimum multiple-emulsions by adding 1% PVA to this. Multi-emulsions manufactured in this study had a 70% efficiency of encapsulation rate and grain ratio was 800 nm and have shown enteric stability and efficiency.
  1. Im JS, Lee SK, Bai BC, Lee YS, J. Ind. Eng. Chem., 18(1), 325 (2012)
  2. Ganesh M, Hemalatha P, Mei PM, Rajasekar K, Jang HT, J. Ind. Eng. Chem., 18(2), 684 (2012)
  3. The Korean Intellectual Property Office (KIPO), Nanomed. Technol. 3.8 (2006) 166.
  4. Kim YC, Kim GM, Kim SW, Joung HS, Joung SY, Polym. Phys. J., 15(4), 396 (2004)
  5. Lee BJ, Shin YH, Seo SH, Sa HG, Joun YG, Lee CH, Lee MH, Shim CG, Jee SC, et al., Manufacturing Pharmaceutics, Manufacturing Pharmaceutics Division at Korean Council of Colleges of Pharmacy, 2004p. 461.
  6. Choi HS, Kim SW, Yun DI, Khang G, Rhee JM, Kim YS, Lee HB, Polymer, 1334 (2004)
  7. Fleisch H, Bisphosphonates in Born Disease, 2nd ed., Parthenon Publishing, London, 1995, The laboratory to the patent.
  8. Gertz BJ, Clin. Pharmacol. Ther., 58(3), 288 (1995)
  9. Amore Pacific Co., Sustained-releasing injectable formulation for the treatment or prevention of bone-related diseases comprising bisphosphonate-containing polymeric microparticles, a patent (10-0648515-0000), 2006.
  10. AmorePacific Co., The preparation method of macromolecular particles that enables continuous drug efflux, a patent (10-0709015-0000), 2007.
  11. Thomson Pdr, Physicians Desk Reference, 53rd ed., Micromedex Health Care Series, 1999, p. 1795.
  12. Sweetman, Sean C, Martindale: The Extra Pharmacapoeia, 35th ed., 2007, p. 776.